Josh Enomoto

Josh Enomoto

As a financial analyst who has engaged in multimillion dollar projects with Global 500 companies, Joshua Enomoto provides an acute perspective of the investment markets.

A graduate of the University of California, San Diego, his professional experience covers multiple industries, including healthcare, civil engineering, and consumer electronics. Past contributions include leading the resolution of a critical liabilities dispute between two major electronics companies, and being awarded a speaking engagement in Tokyo, Japan, regarding supply chain efficiency protocols.

Currently based in San Diego, Josh is also an avid music composer and audio engineer, and spends his free time with multimedia pursuits.

Recent Articles

Why the Perplexing Science of Vaccines Keeps Novavax Around

Though Novavax is behind in the clinical trial race, that doesn’t necessarily mean NVAX stock is done for. However, investors who want to take a bet must do so very carefully.

The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals

Although vaccine plays are inherently risky, the recent robust rally in INO stock is backed by strong and compelling science.

Beyond Meat Stock Has Competition and It’s Tasty

There’s no question that Beyond Meat stock is capitalizing on the enormous popularity of plant-based meat. However, rising competition means that commoditization is a very real threat.

Why Novartis’ Absence From the Covid-19 Vaccine Race Is a Benefit

Although it’s one of the major pharmaceuticals, Novartis didn’t directly jump into the vaccine race. That might have been the best move for Novartis stock.

Don’t Be Afraid To Be Skeptical About Kensington Capital Stock

Thanks to the enormous interest around EVs and associated businesses, Kensington Capital stock has skyrocketed off the potential of solid-state batteries. But this narrative has always been a tricky one for even the best manufacturers.